Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02151981 · OUTCOME

Secondary: Overall Survival (OS)

AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer · Source last updated 2025-01-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
From date of randomization until time of final OS analysis, a median follow-up of 43 months

Groups in this outcome

Osimertinib 80mg

Daily single dose of Osimertinib 80mg

Chemotherapy

Platinum-based doublet chemotherapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Osimertinib 80mg279
Chemotherapy140

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Osimertinib 80mg26.8Not reported23.531.5Not reported
Chemotherapy22.5Not reported20.228.8Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    0.67
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    1.13
    estimate Comment
    A hazard ratio \<1 favours Osimertinib 80 mg
    group Ids
    1. OG000
    non Inferiority Type
    SUPERIORITY_OR_OTHER_LEGACY
    p Value
    0.277
    param Type
    Hazard Ratio (HR)
    param Value
    0.87
    statistical Method
    Log Rank
Complete source fields
analyses
  1. ci Lower Limit
    0.67
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    1.13
    estimate Comment
    A hazard ratio \<1 favours Osimertinib 80 mg
    group Ids
    1. OG000
    non Inferiority Type
    SUPERIORITY_OR_OTHER_LEGACY
    p Value
    0.277
    param Type
    Hazard Ratio (HR)
    param Value
    0.87
    statistical Method
    Log Rank
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        23.5
        upper Limit
        31.5
        value
        26.8
      2. group Id
        OG001
        lower Limit
        20.2
        upper Limit
        28.8
        value
        22.5
denoms
  1. counts
    1. group Id
      OG000
      value
      279
    2. group Id
      OG001
      value
      140
    units
    Participants
dispersion Type
95% Confidence Interval
groups
  1. description
    Daily single dose of Osimertinib 80mg
    id
    OG000
    title
    Osimertinib 80mg
  2. description
    Platinum-based doublet chemotherapy
    id
    OG001
    title
    Chemotherapy
param Type
MEDIAN
reporting Status
POSTED
time Frame
From date of randomization until time of final OS analysis, a median follow-up of 43 months
title
Secondary: Overall Survival (OS)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice